Gruppo di Studio Ginecologia – Prodotti

Contouring of emerging organs-at-risk (OARS) of the female pelvis and interobserver variability: A study by the Italian association of radiotherapy and clinical oncology (AIRO)

Ottobre 12, 2023

Visualizza Documento

Definitive chemoradiation in vulvar squamous cell carcinoma: outcome and toxicity from an observational multicenter Italian study on vulvar cancer (OLDLADY 1.1)

Settembre 29, 2023

Visualizza Documento

“Survey sulle Conoscenze e Atteggiamenti relativi all’Utilizzo della Radioterapia Stereotassica nella Gestione del Tumore ovarico oligometastatico/persistente/ricorrente (MPR-OC) in Trattamento con PARP-Inibitori” – deadline 15-07-2023

Maggio 24, 2023

Lettera di invito alla compilazione Link per la Compilazione della Survey

EFFICACY AND SAFETY OF STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OLIGOMETASTATIC UTERINE CANCER (MITO-RT2/RAD STUDY): A LARGE, REAL-WORLD STUDY IN COLLABORATION WITH AIRO GYN, MITO and MaNGO Groups

Maggio 24, 2023

Visualizza Documento

Vaginal Toxicity Management

Febbraio 20, 2023

Visualizza Documento

Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups

Novembre 12, 2022

Visualizza Documento

Postoperative treatment of intermediate-risk early stage cervical cancer: results of a survey from the Gynecology Study Group in the AIRO Gyn and MITO Groups

Giugno 8, 2022

Visualizza Documento

Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/ RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups

Febbraio 3, 2022

Visualizza Documento

Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/ persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/ RAD)

Giugno 1, 2021

Visualizza Documento

Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review

Febbraio 1, 2021

Visualizza Documento